… court validated its patents for the multiple-sclerosis drug Copaxone and found purported generic versions by Mylan Inc. ( MYL ) and Momenta Pharmaceuticals Inc. (MNTA) infringe those patents. The decision by the U.S. District Court for the Southern …

… multiple-sclerosis drug Copaxone, helping the generic drug giant to beat back threats to its top-selling drug from rivals Mylan Inc. ( MYL ) and Momenta Pharmaceuticals Inc. (MNTA). Shares of Teva jumped 5.4% in midday trade Monday to $40.06, while the …

DOW JONES NEWSWIRES Mylan Inc.'s ( MYL ) first-quarter earnings rose 24% as the company's sales improved ..... manufactures the rival Epi-Pen auto-injector and Mylan Inc.'s ( MYL ) specialty unit markets and distributes it in the U.S. EpiPen …

… 8%) from $41.65 on March 29, 2012. The stock is trading 10.2% above its 200-day moving average. Mylan (NASDAQ: MYL ) was down on high volume, trading with volume of 8.9 million, or 1.7 its average daily volume. Closing at $21.69 …

… in the United States to enforce Orion's U.S. patents covering its product Stalevo against Mylan Pharmaceuticals Inc. ( MYL ). MAIN FACTS: -Mylan seeks authorisation to produce and market generic tablets in the United States, with carbidopa, levodopa …

… enforceable," Bruce N. Kuhlik, executive vice president and general counsel of Merck, said in a press release. Mylan Inc. ( MYL ) had applied for U.S. Food and Drug Administration approval to sell generic versions of Vytorin and Zetia before the patent …

… The stock is trading at 97.8% of its 50-day moving average and 94.2% of its 200-day moving average. Mylan (NASDAQ: MYL ) was trading down on above-average volume with 6.9 million shares moving, or 1.8 its average daily volume. Shares were …